Cargando…

Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients

BACKGROUND: Long acting antiretroviral drugs represent a promising approach for chronic treatment of HIV infection. Here, we study the efficacy and safety of albuvirtide (ABT), an HIV-1 fusion inhibitor with a half life of 11–12 days in human. METHODS: ABT was evaluated in a 7-week, open-label and r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Hongwei, Jin, Ronghua, Yao, Cheng, Zhang, Tong, Wang, Meixia, Xia, Wei, Peng, Haiyan, Wang, Xiaojuan, Lu, Rongjian, Wang, Changjin, Xie, Dong, Wu, Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748529/ https://www.ncbi.nlm.nih.gov/pubmed/26865854 http://dx.doi.org/10.1186/s12981-016-0091-1

Ejemplares similares

Tolerability and Adherence of Antiretroviral Regimens Containing Long-Acting Fusion Inhibitor Albuvirtide for HIV Post-Exposure Prophylaxis: A Cohort Study in China
por: Nie, Jingmin, et al.
Publicado: (2021)

Biophysical Property and Broad Anti-HIV Activity of Albuvirtide, a 3-Maleimimidopropionic Acid-Modified Peptide Fusion Inhibitor
por: Chong, Huihui, et al.
Publicado: (2012)

Tolerability and effectiveness of albuvirtide combined with dolutegravir for hospitalized people living with HIV/AIDS
por: Liu, Huanxia, et al.
Publicado: (2023)

Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study
por: Su, Bin, et al.
Publicado: (2020)

HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy
por: Martin, Allison, et al.
Publicado: (2013)

Rescue therapy with an albuvirtide-based antiretroviral regimen in an HIV-infected child with multidrug resistance and multiple opportunistic infections: a case report
por: Tang, Wei, et al.
Publicado: (2023)

CSF LPV concentrations and viral load in viral suppressed patients on LPV/r monotherapy given once daily
por: Tiraboschi, Juan, et al.
Publicado: (2014)

Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
por: Deng, Lisi, et al.
Publicado: (2020)

Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1
por: Maroldo, L, et al.
Publicado: (2010)

Enfuvirtide−PEG conjugate: A potent HIV fusion inhibitor with improved pharmacokinetic properties
por: Cheng, Shuihong, et al.
Publicado: (2016)

Status of coupling compensation for the LPv3 optics in 1995
por: Verdier, A
Publicado: (1995)

Comparing albuvirtide plus ritonavir-boosted lopinavir regimen to two nucleotide reverse transcriptase inhibitors plus ritonavir-boosted lopinavir in HIV-infected individuals who failed initial treatment: a retrospective comparative cohort study
por: Chen, Liyu, et al.
Publicado: (2022)

Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus
por: Yu, Danwei, et al.
Publicado: (2021)

Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action
por: Wang, Chen, et al.
Publicado: (2019)

Pursuing use of optimal formulations for paediatric HIV epidemic control – a look at the use of LPV/r oral pellets and oral granules
por: Malati, Christine Y, et al.
Publicado: (2019)

Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection
por: Lan, Qiaoshuai, et al.
Publicado: (2021)

HIV drug resistance profile of HIV-1 CRF 01_AE protease and integrase coding regions in HIV infected Cambodian patients failing LPV-based 2(nd) line antiretroviral regimen
por: Nouhin, Janin, et al.
Publicado: (2011)

Evolution of Framingham cardiovascular risk score in HIV-infected patients initiating EFV- and LPV/r-based HAART in a Latin American cohort
por: Cecchini, Diego, et al.
Publicado: (2014)

Outcomes related to 4864 pregnancies with exposure to lopinavir/ritonavir (LPV/r)
por: Tookey, Pat, et al.
Publicado: (2014)

A deterministic approach for design of supervisory control of LPV systems with delay
por: Zahid, Ch. Nauman, et al.
Publicado: (2021)

Self-Scheduled LPV Control of Asymmetric Variable-Span Morphing UAV
por: Lee, Jihoon, et al.
Publicado: (2023)

An LPV Adaptive Observer for Updating a Map Applied to an MAF Sensor in a Diesel Engine
por: Liu, Zhiyuan, et al.
Publicado: (2015)

A Protein-Based, Long-Acting HIV-1 Fusion Inhibitor with an Improved Pharmacokinetic Profile
por: Xu, Wei, et al.
Publicado: (2022)

HRQoL improves in treatment-naïve HIV-1 subjects initiated on lopinavir/ritonavir (LPV/r) with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC)
por: Baran, RW, et al.
Publicado: (2010)

Pilot, Randomized Study Assessing Safety, Tolerability and Efficacy of Simplified LPV/r Maintenance Therapy in HIV Patients on the 1(st) PI-Based Regimen
por: Cahn, Pedro, et al.
Publicado: (2011)

Current Efavirenz (EFV) or Ritonavir-Boosted Lopinavir (LPV/r) Use Correlates with Elevate Markers of Atherosclerosis in HIV-Infected Subjects in Addis Ababa, Ethiopia
por: Gleason, Rudolph L., et al.
Publicado: (2015)

LPV modeling of nonlinear systems: A multi‐path feedback linearization approach
por: Abbas, Hossam S., et al.
Publicado: (2021)

Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r+3TC for initial ART in HIV infected adults
por: Gatell, Josép M, et al.
Publicado: (2014)

Sargassum fusiforme fraction is a potent and specific inhibitor of HIV-1 fusion and reverse transcriptase
por: Paskaleva, Elena E, et al.
Publicado: (2008)

Three-Drug Regimens Containing Integrase Inhibitor Show Good Efficacy and Safety in Treatment-Naive Patients With HIV-1: A Bayesian Analysis
por: Zhang, Ke, et al.
Publicado: (2021)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

LPV Control for the Full Region Operation of a Wind Turbine Integrated with Synchronous Generator
por: Cao, Guoyan, et al.
Publicado: (2015)

Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China
por: Huang, Xiaojie, et al.
Publicado: (2019)

ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults
por: Orkin, C, et al.
Publicado: (2010)

144-week outcomes of lopinavir/ritonavir (LPV/r)-based first-line ART in 1,409 HIV-infected patients: data from the German STAR/STELLA cohort
por: Wolf, Eva, et al.
Publicado: (2014)

Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men
por: Han, Kelong, et al.
Publicado: (2022)

Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients
por: Berno, Giulia, et al.
Publicado: (2014)

Fusion Proteins CLD and CLDmut Demonstrate Potent and Broad Neutralizing Activity against HIV-1
por: Fu, Ming, et al.
Publicado: (2022)

Selected HIV-1 Env Trimeric Formulations Act as Potent Immunogens in a Rabbit Vaccination Model
por: Heyndrickx, Leo, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_g0e4k6lls1nd0lap3d3irgc3eo